Ocugen advances Phase 1/2 trial for eye disease candidate

seekingalpha04-05

Ocugen (NASDAQ:OCGN) shares traded higher on Friday after the company said its Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy would advance to test a higher dose...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2425331562?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495604593/image_1495604593.jpg","is_english":true,"pubTime":"2024-04-05 22:56","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2425331562","market":"hk","top_or_hot":-1,"title":"Ocugen advances Phase 1/2 trial for eye disease candidate","media":"seekingalpha","content":"<div>\n<p>Ocugen (NASDAQ:OCGN) shares traded higher on Friday after the company said its Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy would advance to test a higher dose...</p>\n\n<a href=\"https://seekingalpha.com/news/4087603-ocugen-stock-gains-as-study-for-eye-disease-therapy-advances\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen advances Phase 1/2 trial for eye disease candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen advances Phase 1/2 trial for eye disease candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-05 22:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4087603-ocugen-stock-gains-as-study-for-eye-disease-therapy-advances><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen (NASDAQ:OCGN) shares traded higher on Friday after the company said its Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy would advance to test a higher dose...</p>\n\n<a href=\"https://seekingalpha.com/news/4087603-ocugen-stock-gains-as-study-for-eye-disease-therapy-advances\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://seekingalpha.com/news/4087603-ocugen-stock-gains-as-study-for-eye-disease-therapy-advances","article_id":"2425331562","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495604593/image_1495604593.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2425331562","pubTimestamp":1712328985,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Ocugen (NASDAQ:OCGN) shares traded higher on Friday after the company said its Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy would advance to test a higher dose","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen","BK4588":"碎股","BK4568":"美国抗疫概念","ALPMF":"Astellas Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4563":"昨日强势股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药","APLS":"Apellis Pharmaceuticals Inc.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4505":"高瓴资本持仓"},"translate_title":"Ocugen推进候选眼病1/2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALPMF":1,"APLS":1,"OCGN":1},"content_text":"Ocugen (NASDAQ:OCGN) shares traded higher on Friday after the company said its Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy would advance to test a higher dose following early signs of tolerability. The update relates to the Phase 1 portion of the trial designed to test three dose levels of OCU410. The one-time therapy is expected to rival FDA-approved GA drugs such as Syfovre and Izervay from Apellis Pharma (APLS) and Astellas Pharma (OTCPK:ALPMF), respectively. Citing data from three patients who received initial doses, Ocugen (OCGN) said serious adverse events related to OCU410 have yet to be seen, and the trial’s Data and Safety Monitoring Board recommended that the study be advanced to medium dose cohorts. “I believe that this marks a critical next step towards determining the optimal dosing regimen and an important milestone for the clinical development of OCU410,” Peter Chang, the chair of the OCU410 clinical study, remarked.  More on Ocugen  Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking Alpha’s Quant Rating on Ocugen Historical earnings data for Ocugen","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425331562"}